North & North · Research
Two repair peptides, finally measured together
Your stomach makes one of these and your cells are full of the other. BPC-157 is a fragment pulled from a protein that protects tissue. TB-500 is a synthetic copy of one that holds cells together. Both are studied in repair, and in 2026 they were finally tested side by side.
The question everyone asks
Two peptides studied in the same territory, tested separately and as a pair. The pair did not come out ahead.
Most material about these two treats them as a set, so the 2026 study is worth knowing about. It is preclinical, and it ran four arms: a control, each compound on its own, and the two combined. On the measures it recorded, tendon strength and the organisation of the healing tissue, TB-500 showed the clearest separation from control, BPC-157 moved the same way without reaching significance on its totals, and the combination did not add anything over either compound by itself. That is one preclinical study on one kind of repair, and it is the only direct comparison published so far, which is exactly why it is worth reading rather than taking on trust.
Side by side
| Comparison point | BPC-157 | TB-500 |
|---|---|---|
| Where it comes from | A fragment of a protein found in the stomach. | A synthetic copy of Thymosin Beta-4, full 43 amino acid sequence. |
| What it is studied for | Tendon, ligament, muscle and gut repair. | Cell movement and tissue repair, plus cardiac research. |
| How it is described as working | Nudging growth factor signaling and blood vessel response already underway. | Acting on actin, the scaffolding that governs how cells move. |
| Human studies underway | None that withstands checking. One trial was registered in 2015 and its status has not been updated since. | None on this material. Thymosin Beta 4 has been studied in people since 2006, in other preparations. |
| In the 2026 preclinical head to head | Moved in the same direction as TB-500 without reaching significance on the totals. | Reached statistical significance on tendon strength and tissue architecture. |
| What North & North supplies | Research material only, 5mg, >99% purity. | Research material only, 10mg, >99% purity. |
Reading the research
BPC-157
The broader body of work. If the question is how a repair signal behaves across several kinds of tissue at once, muscle, tendon, ligament, bone and gut, this is where the published record is widest. Almost all of it is preclinical: the one registered human trial is a Phase 1 from 2015 that was never updated again.
TB-500
The one with the cleaner mechanism. Actin handling is a specific, measurable thing, which is part of why it separated from control most clearly in the head to head. Its human work sits in cardiac research rather than sports injury.
Current work
Neither compound has controlled human evidence behind it, and saying otherwise was a mistake this page made. It previously reported that both moved into human study in 2026. The BPC-157 trial it cited came from a sponsor whose registry submissions include records that describe themselves as fictional, and it has been removed. What remains for BPC-157 is a single trial registered in 2015 whose status has not been updated since.
TB-500 is a subtler case and worth stating precisely, because the name is used for two different things. Thymosin Beta 4 genuinely has been studied in people since 2006, in wound healing, pressure ulcers and the eye. Some material sold elsewhere as TB-500 is a short fragment of that protein; what North & North supplies is the full 43 amino acid sequence, which is the same length as the protein those studies used. Even so, those trials used their own recombinant and topical preparations, so read any claim about TB-500 human research carefully: most of it is really about a specific formulation of Thymosin Beta 4 rather than about this material.
The head to head sits alongside that human work rather than above it. It is a single preclinical study on one kind of repair, so it establishes nothing about people. What it does give, for the first time, is the two compounds measured under the same conditions. Read it for the comparison, not for a conclusion.
Every source below was opened and read before it was cited. Nothing on this page is a claim about what either compound does.
Common questions
They are studied in the same territory but they are not related molecules. BPC-157 is a fragment taken from a protein your stomach makes to protect tissue. TB-500 is a synthetic copy of a protein your cells already keep in quantity to hold their internal scaffolding together.
Some study designs do. A 2026 preclinical head to head tested each on its own and both in combination, and the combination did not outperform either one alone on the measures it recorded. That is one study, and it establishes nothing about people, but it does make each a cleaner subject on its own than the two together.
They are close, and they are different in shape. BPC-157 has the larger body of work overall, though its only registered human trial is a Phase 1 from 2015 whose record was never updated again. TB-500 has fewer studies, and the human work on Thymosin Beta 4 used other preparations rather than the material sold here. Neither has controlled human evidence behind it.
No. Some material sold under the TB-500 name is a short fragment of Thymosin Beta-4. North & North supplies the full 43 amino acid sequence, and findings for one do not automatically transfer to the other.
Neither is an approved drug. Both are supplied by North & North as research material only, not for human consumption or therapeutic use.
Go deeper
Catalog access
Create a quick and easy free account to shop BPC-157 and TB-500 and other peptides.
Free to create. You will verify your email address before the catalog opens.
The statements made on this website have not been evaluated by the U.S. Food and Drug Administration. Products offered through this website and information presented here are not intended to diagnose, treat, cure, or prevent any disease or medical condition. North & North LLC is not a pharmacy, compounding pharmacy, compounding facility, medical provider, or outsourcing facility. All products are sold strictly for research, laboratory, or analytical purposes only and are not intended for human consumption. Customers are solely responsible for compliance with all applicable federal, state, and local laws governing the purchase, possession, handling, and use of research-use compounds.
